Understanding the Conflict Between Whoop and the FDA
Background of the Issue
The distinction between medical and wellness products can often become unclear. A recent incident involving Whoop highlights the regulatory challenges faced by developers of wearable technology as they integrate advanced features. This summer, Whoop received a warning letter from the Food and Drug Administration (FDA) after introducing a blood pressure feature without prior regulatory approval.
Whoop’s Position on Blood Pressure Insights
In response to the FDA’s warning, Whoop has maintained that the blood pressure feature is a wellness tool rather than a medical device. The FDA, however, contends that blood pressure measurement is intrinsically linked to medical diagnosis and thus falls under its jurisdiction. Experts believe that the FDA is unlikely to change its stance on this matter, illustrating the ongoing struggle to delineate wellness from medical functionalities in wearable technology.
Details of Whoop’s Blood Pressure Feature
Feature Overview
Whoop introduced its blood pressure insights feature in May, utilizing data from heart rate, heart rate variability, and blood flow patterns during sleep to estimate systolic and diastolic blood pressure ranges upon waking. This feature is included in Whoop’s premium membership plan, which also offers electrocardiogram capabilities and heart rhythm alerts.
Company’s Response to FDA Warning
Since receiving the warning letter in July, Whoop has stood firm in its position. The company has publicly defended its feature, with CEO Will Ahmed appearing on CNBC to express disagreement with the FDA’s classification. In a summary of their response to the FDA shared with MedTech Dive, Whoop stated, “We firmly disagree with the FDA’s claims that Blood Pressure Insights qualifies as a regulated medical device.” The company asserts that it does not believe the FDA has the authority to regulate this product and intends to continue offering the feature. Ahmed recently described discussions with the FDA as having taken a “constructive” turn, indicating that Whoop is seeking a resolution.
Expert Opinions on the FDA’s Stance
Anticipated Outcomes
Experts in the field, including Mark Gardner, founder and managing partner of Gardner Law, suggest that the FDA is likely to maintain its position. Gardner, who personally uses Whoop’s wristband, expressed skepticism about the company’s chances against the FDA, stating, “The fact that they think they can just add a blood pressure feature and do these things without getting them approved by the FDA, it’s just not going to happen.”
Regulatory Enforcement Process
Typically, the FDA issues warning letters to allow companies an opportunity to address identified issues. While companies may choose to contest these letters, Gardner noted that the FDA is generally correct in its assessments. Following a warning letter, the FDA has the authority to escalate enforcement actions, which could involve the Department of Justice, search warrants, product seizures, or consent decrees to ensure compliance.